Page 11 of 17

SU24.2-3 | Pancreatic Endocrine Tumours — SDL Guide (Part 2)

Principles of Management and Prognosis

Management of a pancreatic endocrine tumour combines control of the hormonal syndrome with definitive treatment of the tumour, and the approach depends on the tumour type and on whether disease is localised or metastatic. For a localised, benign insulinoma, surgical removal is curative — a small, superficial, benign tumour can often be enucleated, while a less accessible lesion may need a formal pancreatic resection; before and during surgery, hypoglycaemia is controlled (for example with diet, dextrose and agents such as diazoxide that suppress insulin release). For a gastrinoma / Zollinger-Ellison syndrome, the cornerstone of immediate management is high-dose proton pump inhibitors (PPIs) to control the dangerous acid hypersecretion and heal the ulcers, after which a localised gastrinoma may be resected; because gastrinomas are frequently malignant and may have spread, surgical cure is less often achievable than with insulinoma. For metastatic or unresectable disease, the syndrome and tumour growth are controlled with somatostatin analogues (such as octreotide/lanreotide, which suppress hormone secretion and slow growth in receptor-positive tumours), with further options including targeted agents, peptide-receptor radionuclide therapy and chemotherapy for selected patients. A vital caveat in any patient with MEN-1 is that the management of the pancreatic tumour must be planned alongside the parathyroid and pituitary disease, often as part of a coordinated, sometimes staged, surgical strategy. Prognosis is generally good for the benign insulinoma (frequently curable) and more variable for gastrinomas and the rarer tumours, depending heavily on whether the tumour is malignant and whether metastases are present at diagnosis. Set within the wider picture of pancreatic disorders (SU24.3), the same principles recur: define the problem precisely, treat the curable surgically, and control with medical therapy what cannot be cured.

Check Your Understanding

Return to the two patients in the hook and reason through them with the confirm-first framework. The 35-year-old woman with recurrent fasting episodes of confusion and sweating, documented hypoglycaemia and prompt relief on eating has Whipple's triad and an insulinoma: confirm it with a supervised 72-hour fast showing hypoglycaemia with inappropriately raised insulin and C-peptide, localise the usually small, usually benign tumour with CT/MRI, EUS and somatostatin-receptor imaging, screen for MEN-1, and cure her by enucleation or resection. The 50-year-old man with refractory, atypically sited peptic ulcers and unexplained diarrhoea has a gastrinoma causing Zollinger-Ellison syndrome: confirm it with a raised fasting gastrin and high acid output, control the acid immediately with high-dose PPIs, localise the tumour, and recognise that, being often malignant, it may have already spread. Use these to self-test the competencies this module covers. First, can you classify PNETs as functioning or non-functioning and name the syndrome, hormone and malignant tendency of each functioning type? Second, can you describe the confirm-first/localise-second investigation — the 72-hour fast with insulin and C-peptide, the fasting gastrin with acid output, and the localising and somatostatin-receptor imaging — and the MEN-1 screen? Third, can you outline management (surgical cure of localised insulinoma, PPIs and resection for gastrinoma, somatostatin analogues for metastatic disease) and integrate it into the overall approach to pancreatic disorders? The questions that follow check exactly these links.